All samples·Sample analysis
Get your own pass — $199
granted.bioAll samples
Analysis

radioligand therapy for prostate cancer

Overview
  • Dashboard
Analysis
  • What Surprised Us
  • Field Maturity
  • Funding Landscape
  • Competitive Topology
  • White Space
  • Market Context
Data
  • Projects115
  • Clinical Trials500
  • Patents29
  • Publications646
  • Organizations52
  • Researchers125
Reference
  • Methodology
Back
radioligand therapy for prostate cancerOrganizationsUNIVERSITY OF MICHIGAN AT ANN ARBOR

UNIVERSITY OF MICHIGAN AT ANN ARBOR

Projects attributed to UNIVERSITY OF MICHIGAN AT ANN ARBOR within this analysis sample.

In This Analysis
Projects
2
NIH Funding
$1.2M
Projects(2)
ProjectPICategoryFunding
Enhancing radioligand therapy for prostate cancer with biomarker and dosimetry guided personalization
5R01CA289631-02
DEWARAJA, YUNI KTherapeutics$644K
Bringing Capacity for Theranostic Dosimetry Planning to the Nuclear Medicine Clinic
5R01CA240706-05
DEWARAJA, YUNI KTherapeutics$583K
See UNIVERSITY OF MICHIGAN AT ANN ARBOR’s full platform profile
Cross-source view across the entire granted.bio dataset — projects, trials, patents, and publications spanning every topic, not just this analysis.